Back to Best of 2018 - PARP inhibition role in oncology combination therapy
Best of 2018 - PARP inhibition role in oncology combination therapy

Best of 2018 - PARP inhibition role in oncology combination therapy

Speaker:

Laura Alwan, PharmD BCOP

Product Details

This session will review the use of poly (ADP-ribose) polymerase (PARP) inhibitors in oncology therapy. Key topics include the mechanism of action of PARP inhibitors, clinical trial data that have led to the current U.S. Food and Drug Administration–approved indications, common and important toxicities of this drug class with recommended dose adjustments, and the rationale for choosing a particular PARP inhibitor for a specific patient. Combination therapy with PARP inhibitors will be discussed, as well as suggestions for toxicity management and future directions of PARP inhibitor use.

  • List Price: $35.00 USD
  • Member Price: $25.00 USD
Join and Save!
Log into see if you qualify for a lower price.
HOPA members save $10.00 USD or more!
Become a member